ConductScience.org, home

Paper20690807

Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.

Cronin KA and 4 others. Cancer Invest, 2010. Cited by 151 papers, by iCite.

Cite this record

ConductScience Library. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Papers, record 20690807. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20690807

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.
PubMed
Journal
Cancer Invest
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
151
iCite
Relative citation ratio, by iCite
3.21
iCite
Revised in PubMed
2026-01-27
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cronin KAKathleen A
2Harlan LCLinda C
3Dodd KWKevin W
4Abrams JSJeffrey S
5Ballard-Barbash RRachel

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Population SurveillanceMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
SEER ProgramMajor topic
Black or African American
Asian
Female
Hispanic or Latino
Humans
Middle Aged
Multivariate Analysis
Neoplasm Staging
Prevalence
United States
White People

Source PubMed

Download CSV of topics

Grants22

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
N01-PC-35145NCI NIH HHSUnited StatesPubMedPubMed
N01 PC035133NCI NIH HHSUnited StatesN01PC035133PubMedNIH RePORTER
N01-PC-35139NCI NIH HHSUnited StatesPubMedPubMed
N01-PC-35135NCI NIH HHSUnited StatesPubMedPubMed
N01-PC-35133NCI NIH HHSUnited StatesPubMedPubMed
N01 PC035139NCI NIH HHSUnited StatesN01PC035139PubMedNIH RePORTER
N01 PC035137NCI NIH HHSUnited StatesN01PC035137PubMedNIH RePORTER
N01 PC035142NCI NIH HHSUnited StatesN01PC035142PubMedNIH RePORTER
Z99 CA999999Intramural NIH HHSUnited StatesZ99CA999999PubMedNIH RePORTER
N01 PC035141NCI NIH HHSUnited StatesN01PC035141PubMedNIH RePORTER
N01 PC035138NCI NIH HHSUnited StatesN01PC035138PubMedNIH RePORTER
N01 PC035145NCI NIH HHSUnited StatesN01PC035145PubMedNIH RePORTER
N01-PC-35138NCI NIH HHSUnited StatesPubMedPubMed
N01-PC-35142NCI NIH HHSUnited StatesPubMedPubMed
N01-PC-35137NCI NIH HHSUnited StatesPubMedPubMed
N01 PC035143NCI NIH HHSUnited StatesN01PC035143PubMedNIH RePORTER
N01 PC035136NCI NIH HHSUnited StatesN01PC035136PubMedNIH RePORTER
N01-PC-35141NCI NIH HHSUnited StatesPubMedPubMed
N01-PC-35143NCI NIH HHSUnited StatesPubMedPubMed
N01-PC-35136NCI NIH HHSUnited StatesPubMedPubMed

See all 22 grantsDownload CSV of grants

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116809727HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.J Clin Oncol2006https://conductscience.org/library/papers/16809727PubMed
216085689Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.Ann Oncol2005https://conductscience.org/library/papers/16085689PubMed
318256926
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.
Breast Cancer Res Treat2009https://conductscience.org/library/papers/18256926PubMed
43798106Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987https://conductscience.org/library/papers/3798106PubMed
51351538Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.J Clin Oncol1992https://conductscience.org/library/papers/1351538PubMed
616208704Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu.Cancer2005https://conductscience.org/library/papers/16208704PubMed
72470152Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science1989https://conductscience.org/library/papers/2470152PubMed
81973070HER-2/neu amplification predicts poor survival in node-positive breast cancer.Cancer Res1990https://conductscience.org/library/papers/1973070PubMed
915868434Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.Breast Cancer Res Treat2005https://conductscience.org/library/papers/15868434PubMed
1012048273Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.J Natl Cancer Inst2002https://conductscience.org/library/papers/12048273PubMed
1115917412Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.J Clin Pathol2005https://conductscience.org/library/papers/15917412PubMed
1212529347Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.J Natl Cancer Inst2003https://conductscience.org/library/papers/12529347PubMed
1316236737Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med2005https://conductscience.org/library/papers/16236737PubMed
1416236738Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med2005https://conductscience.org/library/papers/16236738PubMed
1516757721Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA2006https://conductscience.org/library/papers/16757721PubMed

Download CSV of references

Cited by112

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.

PMIDTitleJournalYearIn PapersSource
42955226Economic evaluation of pertuzumab in early versus late settings of HER2-positive breast cancer: a systematic review.Eur J Health Econ2026https://conductscience.org/library/papers/42955226PubMed
42615383Membrane-Bound Multimodal Plasmonic Transducers for Noninvasive, In Situ Monitoring and Control of CAR T Cells Against Heterogeneous Solid Tumors.Adv Mater2026https://conductscience.org/library/papers/42615383PubMed
42123574MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics-Potential to Advance Personalised Approaches in Clinical Trials.Int J Mol Sci2026https://conductscience.org/library/papers/42123574PubMed
42089011Pulmonary Hypertension Following the Use of Trastuzumab Biosimilars.Case Rep Pulmonol2026https://conductscience.org/library/papers/42089011PubMed
42018554Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta-Analysis of a Potential Therapeutic Target.Prostate2026https://conductscience.org/library/papers/42018554PubMed
41979751Mean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy.Discov Oncol2026https://conductscience.org/library/papers/41979751PubMed
41971926Fam-trastuzumab deruxtecan in a patient with metastatic human epidermal growth factor receptor 2-positive breast cancer and pre-existing cardiac failure: a case report.AME Case Rep2026https://conductscience.org/library/papers/41971926PubMed
41612284Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access.BMC Health Serv Res2026https://conductscience.org/library/papers/41612284PubMed
41296586Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement.Indian J Med Res2025https://conductscience.org/library/papers/41296586PubMed
40828885HER2 alterations across solid tumors: implications for comprehensive testing.Oncologist2025https://conductscience.org/library/papers/40828885PubMed
40826168Novel anti-HER2 nanobody-drug conjugates with enhanced penetration of solid tumor and BBB, reduced systemic exposure and superior antitumor efficacy.Acta Pharmacol Sin2026https://conductscience.org/library/papers/40826168PubMed
40715921FKBP10 expression and TP53 mutation predict prognosis and chemotherapy response in triple-negative breast cancer.Discov Oncol2025https://conductscience.org/library/papers/40715921PubMed
40623091Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib.Future Oncol2025https://conductscience.org/library/papers/40623091PubMed
40507330Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study.Cancers (Basel)2025https://conductscience.org/library/papers/40507330PubMed
40490846Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.Int J Cancer2025https://conductscience.org/library/papers/40490846PubMed
40470054Machine learning-based fusion model for predicting HER2 expression in breast cancer by Sonazoid-enhanced ultrasound: a multicenter study.Front Med (Lausanne)2025https://conductscience.org/library/papers/40470054PubMed
40406477Evaluation of pathological complete response rates in breast cancer patients undergoing neoadjuvant therapy.Rev Bras Ginecol Obstet2025https://conductscience.org/library/papers/40406477PubMed
40405946T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective.Gland Surg2025https://conductscience.org/library/papers/40405946PubMed
40192324Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort study.Oncologist2025https://conductscience.org/library/papers/40192324PubMed
40085414Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.Breast Cancer Res Treat2025https://conductscience.org/library/papers/40085414PubMed

See all 112 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20690807

GET https://conductscience.org/api/papers/v1/20690807/grants?page=2